Prognostic/predictive value of 207 serum factors in colorectal cancer treated with cediranib and/or chemotherapy.

Greg Ridgeway, Generalized Boosted Models: A guide to the gbm package ,(2006)

Jerome H. Friedman, Greedy function approximation: A gradient boosting machine. Annals of Statistics. ,vol. 29, pp. 1189- 1232 ,(2001) , 10.1214/AOS/1013203451

Yingmiao Liu, Mark D. Starr, Anuradha Bulusu, Herbert Pang, Nan Soon Wong, Wanda Honeycutt, Anthony Amara, Herbert I. Hurwitz, Andrew B. Nixon, Correlation of angiogenic biomarker signatures with clinical outcomes in metastatic colorectal cancer patients receiving capecitabine, oxaliplatin, and bevacizumab. Cancer Medicine. ,vol. 2, pp. 234- 242 ,(2013) , 10.1002/CAM4.71

Richard M. Goldberg, Current Approaches to First-Line Treatment of Advanced Colorectal Cancer Clinical Colorectal Cancer. ,vol. 4, ,(2004) , 10.3816/CCC.2004.S.002

J M Jürgensmeier, H-J Schmoll, J D Robertson, L Brooks, M Taboada, S R Morgan, D Wilson, P M Hoff, Prognostic and predictive value of VEGF, sVEGFR-2 and CEA in mCRC studies comparing cediranib, bevacizumab and chemotherapy British Journal of Cancer. ,vol. 108, pp. 1316- 1323 ,(2013) , 10.1038/BJC.2013.79

Priti S. Hegde, Adrian M. Jubb, Dafeng Chen, Nicole F. Li, Y. Gloria Meng, Coen Bernaards, Rebecca Elliott, Stefan J. Scherer, Daniel S. Chen, Predictive Impact of Circulating Vascular Endothelial Growth Factor in Four Phase III Trials Evaluating Bevacizumab Clinical Cancer Research. ,vol. 19, pp. 929- 937 ,(2013) , 10.1158/1078-0432.CCR-12-2535

Stephen R. Wedge, Jane Kendrew, Laurent F. Hennequin, Paula J. Valentine, Simon T. Barry, Sandra R. Brave, Neil R. Smith, Neil H. James, Michael Dukes, Jon O. Curwen, Rosemary Chester, Janet A. Jackson, Sarah J. Boffey, Lyndsey L. Kilburn, Sharon Barnett, Graham H.P. Richmond, Peter F. Wadsworth, Mike Walker, Alison L. Bigley, Sian T. Taylor, Lee Cooper, Sarah Beck, Juliane M. Jürgensmeier, Donald J. Ogilvie, AZD2171: A Highly Potent, Orally Bioavailable, Vascular Endothelial Growth Factor Receptor-2 Tyrosine Kinase Inhibitor for the Treatment of Cancer Cancer Research. ,vol. 65, pp. 4389- 4400 ,(2005) , 10.1158/0008-5472.CAN-04-4409

Hai T Tran, Yuan Liu, Amado J Zurita, Ying Lin, Katherine L Baker-Neblett, Anne-Marie Martin, Robert A Figlin, Thomas E Hutson, Cora N Sternberg, Rafael G Amado, Lini N Pandite, John V Heymach, None, Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials Lancet Oncology. ,vol. 13, pp. 827- 837 ,(2012) , 10.1016/S1470-2045(12)70241-3

Scott Kopetz, Paulo M Hoff, Jeffrey S Morris, Robert A Wolff, Cathy Eng, Katrina Y Glover, Rosie Adinin, Michael J Overman, Vincete Valero, Sijin Wen, Christopher Lieu, Shaoyu Yan, Hai T Tran, Lee M Ellis, James L Abbruzzese, John V Heymach, None, Phase II Trial of Infusional Fluorouracil, Irinotecan, and Bevacizumab for Metastatic Colorectal Cancer: Efficacy and Circulating Angiogenic Biomarkers Associated With Therapeutic Resistance Journal of Clinical Oncology. ,vol. 28, pp. 453- 459 ,(2010) , 10.1200/JCO.2009.24.8252

Joachim Drevs, Patrizia Siegert, Michael Medinger, Klaus Mross, Ralph Strecker, Ute Zirrgiebel, Jan Harder, Hubert Blum, Jane Robertson, Juliane M. Jürgensmeier, Thomas A. Puchalski, Helen Young, Owain Saunders, Clemens Unger, Phase I Clinical Study of AZD2171, an Oral Vascular Endothelial Growth Factor Signaling Inhibitor, in Patients With Advanced Solid Tumors Journal of Clinical Oncology. ,vol. 25, pp. 3045- 3054 ,(2007) , 10.1200/JCO.2006.07.2066